Connect with us

Hi, what are you looking for?

Business News

Trans Vaginal Mesh Opt-Outs Continue – settlement matrixes not right

TVM affected women are concerned about the lack of complete documentation of their complications by the third part mesh claim centers.

Los Angeles , California, 07/18/2015 /SubmitPressRelease123/

Headline: but there is a Serious Problem with the Settlement Matrix 

Summary: Current documentation by the Mesh Claims Center, and resultant manufacturer settlement offers, do not come close to covering the life-long needs of women affected by pudendal neuralgia.

 

Life Care Solutions Group, LLC, the leading educational portal on transvaginal mesh (TVM) related pudendal neuralgia, reports that attorneys are receiving calls from their clients because TVM affected women are concerned about the lack of complete documentation of their complications by the third part mesh claim centers.

 

The third party companies which act as mesh claim centers are currently being used to verify procedures performed, product ID, and diagnoses related to transvaginal mesh. Documenting this information is a necessary step which needs to occur prior to formal settlement offers from the manufacturers.

 

Women have been contacting this center regarding their diagnoses of pudendal neuralgia after being implanted with vaginal mesh for both pelvic organ prolapse and stress urinary incontinence. Unfortunately, the current settlement criteria do not adequately address the severity and extent of complications these women are experiencing. This places them at grave risk for not receiving adequate compensation to manage TVM related pelvic damage over their lifetimes.

 

Dr. Greg Vigna, a Pudendal Neuralgia Opt-Out Attorney, states “the settlement matrixes to date do not provide compensation for the worst injured, and do not provide adequate compensation for past damages as well as long term health care needs and future complications for those with pudendal neuralgia.”

 

The pudendal nerve is a major nerve in the pelvis. It controls various pelvic functions and also carries sensation from the internal and external pelvic area (the perineum) to the brain. This nerve has been damaged by mesh in many women, leading to pudendal neuralgia.

 

Pudendal neuralgia is diagnosed by the presence pain in the area served by the pudendal nerve.  There is pain with sitting, ano-rectal pain, numbness of the clitoris, and often severe pain in the perineum that makes it impossible to wear any clothing that presses on the perineal area. Incontinence and inability to have sex are also common.

 

Linda Gross is one woman diagnosed with pudendal neuralgia, who in 2013 had her day in court.  In her case against Ethicon she was awarded $1,000,000 for future medical care as part of her damages. This demonstrates the scope and cost of expected lifetime complications.  Dr. Vigna, who is also a Certified Life Care Planner, estimates that the future medical care costs of his current pudendal neuralgia patients is similar to these figures. However, the current system, matrix and settlement offers are not reflecting these costs.

 

“For those with pudendal neuralgia symptoms there is little reason to accept an inadequate settlement that basically guarantees there will not be enough funding to cover future surgeries, physical therapy, lost time at work and psychological distress over the rest of one’s lifetime” adds Dr. Vigna.

 

Dr. Greg Vigna

Life Care Solutions Group

800-761-9206

 

News Provided By: Submit Press Release 123 

 

Newsroom powered by Online Press Release Distribution – SubmitMyPressRelease.com

Like Us on Facebook

You May Also Like

Business

State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...

press release

Barrington Research Analyst James C.Goss reiterated an Outperform rating on shares of IMAX Corp IMAX with a Price target of $20. As theaters...